论文部分内容阅读
目的比较高度选择性的血管紧张素Ⅱ受体拮抗剂(ARB)缬沙坦与血管紧张素转换酶抑制剂(ACEI)西拉普利对高血压患者微量蛋白尿排泄的影响。方法选择60例原发性高血压合并有微量蛋白尿患者,随机分为缬沙坦组(n=30)和西拉普利组(n=30),分别予以缬沙坦片80mg,每日1次及西拉普利片2.5mg,每日1次,治疗12周,观察治疗前后血压及尿微量蛋白值,并进行比较。结果两组患者经12周治疗,血压降至正常,微量尿蛋白排泄量明显减少(P<0.01),且两者疗效相似(P>0.05)但西拉普利组有2例出现咳嗽而改用其他药物。结论ARB及ACEI可有效减少高血压患者微量蛋白尿排泄量。
Objective To compare the effects of valsartan and angiotensin converting enzyme inhibitor (ACEI), a highly selective angiotensin Ⅱ receptor antagonist (ARB), on the excretion of microproteinuria in hypertensive patients. Methods Sixty patients with essential hypertension complicated with microalbuminuria were randomly divided into valsartan group (n = 30) and cilazapril group (n = 30), and were given valsartan tablets 80mg daily 1 and cilazapril 2.5mg, 1 day, for 12 weeks, before and after treatment to observe blood pressure and urine protein value, and compared. Results After 12 weeks treatment, blood pressure dropped to normal and urinary protein excretion decreased significantly in both groups (P <0.01), and the curative effect was similar between the two groups (P> 0.05). However, two patients in Cilazapril group changed their cough With other drugs. Conclusion ARB and ACEI can effectively reduce the microalbuminuria excretion in hypertensive patients.